Athenex announces uk mhra validation of the marketing authorization application for oral paclitaxel and encequidar for review

Buffalo, n.y., nov. 29, 2021 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its marketing authorization application (maa) for oral paclitaxel and encequidar (oral paclitaxel) for the treatment of advanced breast cancer has been validated by the united kingdom's (uk) medicines and healthcare products regulatory agency (mhra) for review . the application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided.
ATNX Ratings Summary
ATNX Quant Ranking